In vivo administration of TLR9 agonist reduces the severity of experimental autoimmune encephalomyelitis. The role of plasmacytoid dendritic cells and B lymphocytes

CNS Neurosci Ther. 2014 Aug;20(8):787-90. doi: 10.1111/cns.12289. Epub 2014 Jun 16.

Authors

Ana Leda F Longhini¹, Mariana P A Santos, Fernando Pradella, Adriel S Moraes, Alliny C Dionete, Marilia D Andrade, Paula G Russini, Elaine C Oliveira, Rosemeire O F dePaula, Guilherme A D Morais, Evelise S M Fonseca, Alessandro S Farias, Leonilda M B Santos

Affiliation

¹ Neuroimmunology Unit, Department of Genetics, Evolution and Bioagents, Institute of Biology, University of Campinas, Campinas, Brazil.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adoptive Transfer / methods
Animals
B-Lymphocytes / drug effects
B-Lymphocytes / physiology*
CD3 Complex / metabolism
Dendritic Cells / drug effects
Dendritic Cells / physiology*
Dinucleoside Phosphates / therapeutic use*
Disease Models, Animal
Encephalomyelitis, Autoimmune, Experimental / chemically induced
Encephalomyelitis, Autoimmune, Experimental / drug therapy*
Encephalomyelitis, Autoimmune, Experimental / pathology*
Flow Cytometry
Forkhead Transcription Factors / metabolism
Mice
Mice, Inbred C57BL
Myelin-Oligodendrocyte Glycoprotein / toxicity
Peptide Fragments / toxicity
Toll-Like Receptor 9 / agonists*

Substances

CD3 Complex
Dinucleoside Phosphates
Forkhead Transcription Factors
Foxp3 protein, mouse
Myelin-Oligodendrocyte Glycoprotein
Peptide Fragments
Toll-Like Receptor 9
myelin oligodendrocyte glycoprotein (35-55)
cytidylyl-3'-5'-guanosine